1603830-53-0

Basic information

• Product Name: 3-(2-{[3-(4-chlorophenyl)pyridin-2-yl]oxy}ethyl)-9-methyl-9H-pyrido[2,3-b]indole
• Synonyms: 3-(2-{[3-(4-chlorophenyl)pyridin-2-yl]oxy}ethyl)-9-methyl-9H-pyrido[2,3-b]indole
• CAS NO: 1603830-53-0
• Molecular Weight: 413.906
• Mol File: 1603830-53-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-(2-{[3-(4-chlorophenyl)pyridin-2-yl]oxy}ethyl)-9-methyl-9H-pyrido[2,3-b]indole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-{[3-(4-chlorophenyl)pyridin-2-yl]oxy}ethyl)-9-methyl-9H-pyrido[2,3-b]indole(1603830-53-0)
• EPA Substance Registry System: 3-(2-{[3-(4-chlorophenyl)pyridin-2-yl]oxy}ethyl)-9-methyl-9H-pyrido[2,3-b]indole(1603830-53-0)

Safety Data

• Hazardous Substances Data: 1603830-53-0(Hazardous Substances Data)

Upstream product

• 1603830-59-6 5-bromo-6-(phenylamino)pyridine-3-carbonitrile 
• 477871-32-2 6-amino-5-bromopyridine-3-carbonitrile 
• 4214-73-7 6-aminonicotinonitrile 
• 1603830-61-0 9-methyl-3-vinyl-9H-pyrido[2,3-b]indole 
• 1603830-31-4 2-(9-methyl-9H-pyrido[2,3-b]indol-3-yl)ethanol 
• 1603830-25-6 9-methyl-9H-pyrido[2,3-b]indole-3-carbaldehyde 
• 139884-24-5 9-methyl-<9H>-pyrido<2,3-b>indole-3-carbonitrile 
• 1679-18-1 4-Chlorophenylboronic acid 

Relevant articles and documents

Design, synthesis and pharmacological evaluation of novel polycyclic heteroarene ethers as PDE10A inhibitors: Part i

We report analogue-based rational design and synthesis of two novel series of polycyclic heteroarenes, pyrrolo[3,2-b]quinolines and pyrido[2,3-b]indoles, tethered to a biaryl system by a methyl-, ethyl- or propyl ether as PDE10A inhibitors. A number of analogues were prepared with variable chain length and evaluated for their ability to block PDE10A enzyme using a radiometric assay. Detailed SAR analyses revealed that compounds with an ethyl ether linker are superior in potency compared to compounds with methyl or propyl ether linkers. These compounds, in general, showed poor metabolic stability in rat and human liver microsomes. The metabolic profile of one of the potent compounds was studied in detail to identify metabolic liabilities of these compounds. Structural modifications were carried out that resulted in improved metabolic stability without significant loss of potency.